MMP9 and rheumatoid arthritis: In the rheumatoid arthritis (RA) model, tetramethylpyrazine (40 mg/kg) significantly decreased MMP-9 expression in synovial cells, thereby delaying joint destruction (Li Y. et al., 2019).